Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

Phase 3

Completed

• Conditions: Primary Immunodeficiency
• Interventions: Biological: Prometic's Immune Globulin Intravenous 10%; Biological: Immune Globulin Intravenous

• Registration Number: NCT02269163
• Lead Sponsor: Prometic Biotherapeutics, Inc.

Brief Summary

Phase 3 multicenter, open-label study of safety, tolerability, efficacy, and pharmacokinetics (PK) of ProMetic's Immune Globulin Intravenous (Human) 10%, the investigational medicinal product \[IMP\]), in Adults and Children with Primary Immunodeficiency Diseases (PIDD).

Detailed Description

This is a pivotal Phase 3, open-label, single-arm, multicenter study to assess the tolerability, safety, efficacy, and Pharmacokinetics of the Investigational Medicinal Product in adults and children with Primary Immunodeficiency Diseases (PIDD). A total of approximately 75 subjects aged 2-80 years will be enrolled in the study. Subjects who switch from an investigational immune globulin or subcutaneous immune globulin (IGSC) are required to receive a stable dose of commercial product (CP), which is a licensed commercially available immune globulin intravenous (IGIV) product for at least 3 cycles before they can be given the Investigational Medicinal Product . This study schema will result in the Commercial Product Treatment Period and Investigational Medicinal Product Treatment Period. All subjects will be treated on an outpatient basis with the Investigational Medicinal Product for approximately 1 year, with the dose and schedule based on their previous IGIV treatment regimen (21-day or 28-day dosing interval). A subset of subjects will participate in a Pharmacokinetics sub-study.

The primary objective of the study is to examine the rate of clinically documented serious bacterial infections (SBIs) in subjects treated with the Investigational Medicinal Product to achieve a rate of less than one SBI per year.

Study Timeline

• Study First Submitted: 2014-10-16
• Study First Submitted QC: 2014-10-16
• Study First Posted: 2014-10-20
• Study Start: 2016-01-26
• Primary Completion: 2019-01-11
• Study Completion: 2019-01-11
• Disposition First Submitted: 2020-01-07
• Disposition First Submitted QC: 2020-02-26
• Disposition First Posted: 2020-02-28
• Results First Submitted: 2021-07-27
• Results First Submitted QC: 2021-07-27
• Results First Posted: 2021-08-20
• Status Verified: 2021-11
• Last Update Submitted: 2021-11-03
• Last Update Posted: 2021-11-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 82

Inclusion Criteria

1. Subject is male or female between the ages of 2 and 80 years at Screening.

2. Female subjects of childbearing potential must agree to employ adequate birth control measures, as determined by their IRB/IEC, for the duration of the study.

3. The subject must have one of the following three diagnoses (isolated PIDD of other types will be excluded):

   • Common variable immunodeficiency
   • X-linked agammaglobulinemia
   • Hyper-IgM syndrome and documented low IgG levels (<4.5 mg/mL [450 mg/dL]).

4. Subjects must have been treated with a stable dose of immune globulin administered intravenously (IGIV) or subcutaneously (IGSC) and has documented trough or steady state IgG levels of ≥ 5 mg/mL.

Exclusion Criteria

1. Subject has secondary immunodeficiency or has been diagnosed with dysgammaglobulinemia or isolated IgG subclass deficiency; has known hypoalbuminemia (<3 gm/dL), protein-losing enteropathy, or nephrotic syndrome.
2. Subject has ever had a history of severe anaphylactic or anaphylactoid reaction to immunoglobulins or other blood products.
3. Subject has a known history of immunoglobulin A (IgA) deficiency and known anti-IgA antibodies, thrombotic event, such as deep vein thrombosis, myocardial infarction, cerebrovascular accident, pulmonary embolism, at any time.
4. Subject has received blood products except IGIV, IGSC, or albumin within the previous 12 months or has participated in another study (except for IGIV, IGSC studies) within the previous 4 weeks.
5. Subject has had cancer in the past 5 years, except for basal cell or squamous cell cancers of the skin.
6. Subject has had a documented active infection within 7 days prior to Screening, or subject is on continuous prophylactic antibiotics.
7. Subject is positive for human immunodeficiency virus (HIV)-1 or HIV-2, a positive hepatitis C virus (HCV) or hepatitis B virus (HBV).
8. Subject has levels of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 times the upper limit of normal (ULN).
9. Subject has serum creatinine >1.5 times the ULN or a severe chronic condition such as renal failure with proteinuria.
10. Subject has anemia with a hemoglobin level ≤8 g/dL.
11. Subject has severe neutropenia with neutrophil count ≤1000 per mmᴧ3 or has lymphopenia with <500 per/ mmᴧ3.
12. Subject is taking prednisone at a dose ≥0.15 mg/kg/day and receiving other immunosuppressive drugs or chemotherapy.
13. Subject has known atrial fibrillation requiring anticoagulant therapy; congestive heart failure (New York Heart Association Class III/IV); cardiomyopathy; or cardiac arrhythmia associated with thromboembolic events, unstable or advanced ischemic heart disease, or hyperviscosity.
14. Subject has known decreased Protein C and/or Protein S levels.
15. Subject is positive for antibodies to β2GPI and/or β2GPI DI at Screening.
16. Female subject who is pregnant, breast-feeding, or planning a pregnancy during the course of the study.
17. A history of epilepsy or multiple episodes of migraine (defined as at least one episode within 6 months of enrolment) not completely controlled by medication, or any condition that is likely to interfere with evaluation of the IMP or satisfactory conduct of the study in the Investigator's opinion.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Prometic IGIV 10% Treatment Period	Prometic's Immune Globulin Intravenous 10%	Subjects will receive Prometic Immune Globulin Intravenous 10%
Gammargard, Gammaplex, Gamunex, or Octogam Treatment Period	Immune Globulin Intravenous	Subjects who enroll in the study while on Gammargard, Gammaplex, Gamunex, or Octogam IGIV Product and need to wait for the scheduled start of Prometic IGIV (10%) treatment will continue on their usual dose and treatment cycle with Gammargard, Gammaplex, Gamunex, or Octogam IVIG Product during this period.

Primary Outcome Measures

Name	Time	Method
Annual Rate of Occurrence of Serious Bacterial Infections (SBI)	One year	SBIs were calculated for each subject as 52n/w, where n is the number of reported SBIs and w is the number of weeks on study. For the combined cohorts only, a 99% one-sided (upper) confidence limit for the incidence rate of SBIs (scaled to represent 12 months exposure if necessary) was derived, and the objective of demonstrating that the true infection rate was below 1 per subject per year was considered established if this upper limit was less than 1. To calculate the confidence limit, a negative binomial regression model will be used. This model includes an overdispersion parameter to account for possible intra-subject correlation as well as the actual time period each subject is on the study as an offset variable.

Secondary Outcome Measures

Name	Time	Method
Trough Levels of IgG (Total) Prior to Each Prometic IGIV 10% Infusion	One year	Subject's total IgG levels will be assessed prior to each Prometic IGIV 10% infusion

Trial Locations

Locations (13)

Allergy Associates of the Palm Beaches; 🇺🇸 North Palm Beach, Florida, United States

Immunoe International Research; 🇺🇸 Centennial, Colorado, United States

Johns Hopkins All Children's Hospital; 🇺🇸 Saint Petersburg, Florida, United States

St. Louis University; 🇺🇸 Saint Louis, Missouri, United States

Bellingham Asthma, Allergy and Immunology Clinic; 🇺🇸 Bellingham, Washington, United States

Fort Wayne Medical Institute; 🇺🇸 Fort Wayne, Indiana, United States

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States

University of California, Irvine; 🇺🇸 Irvine, California, United States

Children's Hospital Los Angeles; 🇺🇸 Los Angeles, California, United States

National Jewish Hospital; 🇺🇸 Denver, Colorado, United States

Rush University Medical Center; 🇺🇸 Chicago, Illinois, United States

Dallas Allergy Immunology; 🇺🇸 Dallas, Texas, United States

Optimed Research; 🇺🇸 Columbus, Ohio, United States